抗精神病药治疗精神分裂症患者减重药物干预:系统综述与网状Meta分析
该系统综述与网状Meta分析纳入95项随机临床试验(合并样本量5898例),评估39种药物干预对接受抗精神病药治疗的精神分裂症谱系障碍患者体重变化的影响。与安慰剂相比,司美格鲁肽、利拉鲁肽、托吡酯、二甲双胍和艾塞那肽与体重降低显著相关,证据确定性为中等。司美格鲁肽和二甲双胍观察到具有临床意义的体重变化(≥5%)。
要点
- 司美格鲁肽减重效果最显著,平均差异为-10.98 kg(95% CI,-13.33至-8.62)。
- 利拉鲁肽、托吡酯、二甲双胍和艾塞那肽也与体重降低显著相关,证据确定性为中等。
- 司美格鲁肽和二甲双胍观察到≥5%的临床有意义体重变化。
核心结论
- 在接受抗精神病药治疗的精神分裂症谱系障碍患者中,不同药物干预的体重相关结局存在显著差异。
- 司美格鲁肽、利拉鲁肽、托吡酯、二甲双胍和艾塞那肽与最大的体重降低相关,且证据确定性最高。
研究设计与样本
- 系统综述与频率随机效应网状Meta分析,纳入95项随机临床试验,共39种药物干预,合并样本量5898例。
- 证据确定性使用CINeMA工具评估。
主要发现
- 与安慰剂相比,司美格鲁肽平均差异为-10.98 kg(95% CI,-13.33至-8.62;k=3;中等确定性)。
- 与安慰剂相比,利拉鲁肽平均差异为-5.43 kg(95% CI,-8.54至-2.33;k=2;中等确定性)。
- 与安慰剂相比,托吡酯平均差异为-3.95 kg(95% CI,-5.89至-2.02;k=5;中等确定性)。
- 与安慰剂相比,二甲双胍平均差异为-3.86 kg(95% CI,-5.02至-2.70;k=16;中等确定性)。
- 与安慰剂相比,艾塞那肽平均差异为-2.97 kg(95% CI,-5.83至-0.11;k=3;中等确定性)。
关键数值与推荐
- 司美格鲁肽和二甲双胍观察到临床有意义的体重变化(≥5%)。
- 雷美替胺、尼扎替丁和阿立哌唑也与减重效果相关,但证据确定性极低。
- 多种药物对其他代谢结局有有益影响,干预间胃肠道不良事件或退出研究无重大担忧。
临床怎么用
- 司美格鲁肽、利拉鲁肽、托吡酯、二甲双胍和艾塞那肽可为临床管理抗精神病药相关体重增加提供指导。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Significant weight gain is a concerning adverse effect of antipsychotic medications experienced by patients with schizophrenia spectrum disorders (SSDs). Its high prevalence and significant contribution to cardiometabolic morbidity in this population warrant better consensus on the management of antipsychotic-induced weight gain and related comorbidity. OBJECTIVES: To evaluate the association between pharmacological interventions and changes in body weight among antipsychotic-treated patients with SSDs. DATA SOURCES: Ovid MEDLINE, Embase, PsycINFO, the Cochrane Central Register of Controlled Trials (CENTRAL), CINAHL, ClinicalTrials.gov, and the International Clinical Trials Registry Platform (ICTRP) Search Portal were searched up to December 5, 2025. STUDY SELECTION: Randomized clinical trials examining any pharmacological intervention for weight reduction in antipsychotic-treated patients with SSDs were included. No restrictions to study duration were applied. DATA EXTRACTION AND SYNTHESIS: A systematic review and frequentist random-effects network meta-analysis was conducted. Certainty in the evidence was assessed using the Confidence in Network Meta-Analysis (CINeMA) tool. The first round of data analysis took place between May 2025 to November 2025 and was updated in December 2025. MAIN OUTCOMES AND MEASURES: The primary outcome was change in body weight following treatment with pharmacological agent vs placebo or standard care. Secondary outcomes included other anthropometric and metabolic parameters. RESULTS: A total of 95 studies examining 39 individual pharmacological interventions were included in this review (pooled N = 5898). The network meta-analysis found that semaglutide (mean difference [MD], -10.98 kg; 95% CI, -13.33 to -8.62; k = 3; moderate certainty), liraglutide (MD, -5.43 kg; 95% CI, -8.54 to -2.33; k = 2; moderate certainty), topiramate (MD, -3.95 kg; 95% CI, -5.89 to -2.02; k = 5; moderate certainty), metformin (MD, -3.86 kg; 95% CI, -5.02 to -2.70; k = 16; moderate certainty), and exenatide (MD, -2.97 kg; 95% CI, -5.83 to -0.11; k = 3; moderate certainty) were associated with the most significant reductions in body weight compared to placebo. Other interventions including ramelteon, nizatidine, and aripiprazole were also found to be associated with weight-reducing effects but with very low certainty of evidence. Clinically meaningful weight change of 5% or greater was observed with semaglutide and metformin. Beneficial effects on other metabolic outcomes were also noted with several of the medications, and there were no major concerns with gastrointestinal adverse effects or leaving the study early (ie, dropouts) between interventions. CONCLUSIONS AND RELEVANCE: This systematic review and network meta-analysis found substantial variability in weight-related outcomes across pharmacological interventions for antipsychotic-treated individuals with SSDs. Semaglutide, liraglutide, topiramate, metformin, and exenatide were associated with the greatest reductions in body weight and were supported by the highest-certainty evidence, providing guidance for clinicians managing antipsychotic-associated weight gain.
引用
- Stogios N, Agarwal SM, Maksyutynska K, et al. Pharmacological Interventions for Weight Reduction in Patients With Schizophrenia Treated With Antipsychotics: A Systematic Review and Network Meta-Analysis. JAMA Psychiatry. 2026. PMID: 42418179. doi:10.1001/jamapsychiatry.2026.1814
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。